CD274 and cancer: Work is ongoing on future iterations of this model which will include additional combination therapies and design elements, as well as additional mechanistic features such as the activation or differentiation of monocyte lineage cells (for instance, macrophages) and incorporating immunosuppressive functions of cancer cells via the PD1-PDL1 axis [75].